Brief: Ac Immune And Takeda Sign Exclusive Option And License Agreement For Active Immunotherapy
13/05/2024 12:27
May 13 (Reuters) - AC Immune SA ACIU.O :
* AC IMMUNE AND TAKEDA SIGN EXCLUSIVE OPTION AND LICENSE
AGREEMENT
FOR ACTIVE IMMUNOTHERAPY TARGETING AMYLOID BETA FOR ALZHEIMER’S
DISEASE
* AC IMMUNE RECEIVES $100M UPFRONT FROM TAKEDA
* AC IMMUNE ELIGIBLE FOR $2.1B IN POTENTIAL MILESTONES
* AC IMMUNE SA - TAKEDA TO FUND FURTHER CLINICAL DEVELOPMENT
POST-OPTION EXERCISE
Source text for Eikon: ID:nGNX6llvlt
Further company coverage: ACIU.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on AC Immune SA
See all newsBrief: Ac Immune To Receive Research Grant From Goradia Family For Development Of Aci-7104 In Parkinson’S Disease
AC Immune Q1 net loss narrows on lower expenses
Brief: AC Immune Announces Amendment To Morphomer ® Tau License And Collaboration Agreement With Lilly
U.S. STOCKS ON THE MOVE-Darden Restaurants, Mastercard, Accenture
U.S. STOCKS ON THE MOVE-Darden Restaurants, Mastercard, Accenture